Published in final edited form as:

Biochim Biophys Acta. 2014 August ; 1840(8): 2460–2470. doi:10.1016/j.bbagen.2014.01.035.

Key roles for the small leucine-rich proteoglycans in renal and pulmonary pathophysiology

Madalina V. Nastase^a, Renato V. Iozzo^b, and Liliana Schaefer^{a,*}

Madalina V. Nastase: madalina.nastase@gmail.com; Renato V. Iozzo: iozzo@kimmelcancercenter.org; Liliana Schaefer: schaefer@med.uni-frankfurt.de

^aPharmazentrum Frankfurt/ZAFES, Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der Goethe-Universität Frankfurt am Main, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany

^bDepartment of Pathology, Anatomy and Cell Biology, and the Cancer Cell Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107 USA

Abstract

Background—Small leucine-rich proteoglycans (SLRPs) are molecules that have signaling roles in a multitude of biological processes. In this respect, SLRPs play key roles in the evolution of a variety of diseases throughout the human body.

Scope of Review—We will critically review current developments in the roles of SLRPs in several types of disease of the kidney and lungs. Particular emphasis will be given to the roles of decorin and biglycan, the best characterized members of the SLRP gene family.

Major Conclusions—In both renal and pulmonary disorders, SLRPs are essential elements that regulate several pathophysiological processes including fibrosis, inflammation and tumor progression. Decorin has remarkable antifibrotic and antitumorigenic properties and is considered a valuable potential treatment of these diseases. Biglycan can modulate inflammatory processes in lung and renal inflammation and is a potential target in the treatment of inflammatory conditions.

General significance—SLRPs can serve as either treatment targets or as potential treatment in renal or lung disease.

Keywords

extracellular matrix; biglycan; decorin; cancer; fibrosis; TGF- β ; Toll-like receptor

© 2014 Elsevier B.V. All rights reserved.

*Corresponding author: Liliana Schaefer, M.D., Pharmazentrum Frankfurt, Institut für Allgemeine Pharmakologie und Toxikologie, Klinikum der JW Goethe-Universität Frankfurt am Main, Haus 74, Z. 3.108a, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany; Tel: +49 69 6301-7899; Fax: +49 69 6301-83027; Schaefer@med.uni-frankfurt.de.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1. Introduction

Small leucine-rich proteoglycans (SLRPs) represent a unique subgroup in the wider class of proteoglycans that have been shown to have, beside their structural function, complex roles in a wide range of extracellular-mediated signaling platforms [1]. SLRPs owe their name to the small size of their protein cores and to the presence of tandem leucine-rich repeats (LRRs) in their primary structure flanked by cysteine-rich clusters [2–4]. We have proposed a nomenclature encompassing 18 SLRP genes (Table 1), encompassing five distinct classes based on their N-terminal cysteine-rich clusters, C-terminal ear repeats, homology at the protein and genomic structure and chromosomal organization [1, 5, 6]. Members of the first three, canonical, SLRP classes, carry both the defining characteristics of a proteoglycan, a protein core structure and one or more glycosaminoglycan (GAG) chains [4, 7]. We have included two new SLRP classes containing members that are not “true” proteoglycans, as they are not substituted GAG chains, with the exception of chondroadherin [8]. However, in common with class I–III, class IV and V SLRPs possess functional similarity, extracellular localization and overall high homology [1, 3].

Following their post-translational modification, SLRPs are secreted into the extracellular space [5] where they play various biological roles by interacting with a wide number of molecular targets. In the extracellular matrix (ECM), SLRPs can either exist in a matrix-bound, sequestered form, or in a soluble form [9–13]. Unfortunately, most of the data collected so far are centered on only a few representative members of this gene family, especially decorin, biglycan, lumican, and fibromodulin, with research concerning the other SLRPs trailing far behind. However, the emerging evidence indicate that SLRPs are essential structural and signaling molecules of the ECM. In their sequestered form, SLRPs serve as regulators of ECM assembly by binding collagen fibrils, primarily through their LRRs [6, 14–20]. Additionally, matrix-bound SLRPs have been shown to be capable of sequestering several molecules, such as growth factors, in the ECM [21–23], thereby inactivating them. As soluble molecules in the ECM, SLRPs play an important role in cell signaling processes, by interacting with several receptors, such as Toll-like receptors (TLR)-2 and -4 [24, 25], vascular endothelial growth factor receptor (VEGFR) [26], epidermal growth factor receptor (EGFR) [27], insulin-like growth factor receptor (IGF-IR) [28], integrins [29–33], low density lipoprotein receptor-related proteins [34, 35] or hepatocyte growth factor (HGF) receptor (Met) [36, 37].

Many of the breakthroughs so far have been the result of studies on mouse models deficient in SLRP genes. Decorin deficiency affects collagen fibril morphology and causes skin fragility [38–40], disrupts angiogenesis [41], alters lung morphology [42] and causes the formation of intestinal tumors [43]. Biglycan-deficient mice suffer as well from collagen fibril abnormalities and further show a propensity to increased bone fragility [23, 40, 44–47]. In fibromodulin deficient mice additional collagen fibril abnormalities [48] are accompanied by impaired alveolar bone formation [49] and delayed wound closure [50], while lumican deficiency causes skin fragility and reduced corneal transparency [51]. In keratocan deficient mice, corneal transparency remains normal, but the mice suffer subtle alterations in the cornea [52]. Finally, epiphykan deficient mice suffer from abnormal bone development and arthrosis [53].

There have been numerous comprehensive reviews on the biology of SLRPs [4–6, 8, 9, 54–61]. Thus, in this review, we will focus on the SLRP roles in renal and pulmonary pathophysiology. We have chosen to address issues of SLRP involvement in renal and lung diseases as the two organs are closely related, and abnormalities in lung function can result from renal disease [62–65].

2. SLRPs in renal diseases

2.1. Role of SLRPs in renal fibrosis

Chronic renal disease frequently leads to renal fibrosis [66–68]. This process involves excessive accumulation of ECM components, leading to glomerulosclerosis, tubulointerstitial fibrosis, and finally to irreversible loss of renal function and end-stage renal disease. One of the main factors involved in the triggering of fibrosis is the transforming growth factor β (TGF- β) cytokine. TGF- β is normally secreted in the glomerulus by podocytes and mesangial cells [69]. In response to different stimuli such as angiotensin, proteinuria, hypoxia or renal damage, TGF- β is activated and induces fibrosis through different mechanisms, of which the most documented is Smad2/3 signaling [69], although non-Smad pathways are also important [70]. Since the original discovery that Chinese hamster ovary cells are growth suppressed by soluble decorin and that this is secondary to a decorin-mediated TGF- β block [71], and since the demonstration that decorin can protect against renal fibrosis [72], it has become apparent that decorin has remarkable antifibrotic properties [73–76], with potential utilization of decorin as an antifibrotic treatment [77].

In the normal kidney, decorin is secreted by renal fibroblasts, and exists mainly in the peritubular space, with trace amounts present in the glomerular space [78, 79]. In fibrotic renal disease, decorin increases and accumulates in areas of tubulointerstitial fibrosis [80–82]. Such a response might suggest that decorin contributes to the development of renal fibrosis. However, while *Dcn*^{-/-} mice do not show any overt renal phenotype, *Dcn*^{-/-} mice with unilateral ureteral obstruction (UUO), a model of renal inflammation and fibrosis, show an aggravated fibrotic response vis-à-vis wild-type mice [83]. The mechanism for this exacerbated fibrosis includes an early apoptosis loss of tubular epithelial cells before upregulation of TGF- β [83]. Additionally, *Dcn*^{-/-} diabetic mice have a reduced lifespan and develop severe nephropathy, correlated with increased levels of glomerular TGF- β and collagen I [83–85]. Moreover, transfection of exogenous decorin alleviates symptoms of rat anti-Thy1.1 nephritis model, and shows promise as a therapeutic method [86].

While the antifibrotic effect of decorin is uncontested, the underlying mechanism is not totally clear. It is certain that decorin directly interacts with TGF- β [71], a property it shares with biglycan and fibromodulin [87]. Through this interaction, decorin would sequester TGF- β in the extracellular matrix, and protect against its deleterious effects [21]. It has also been shown that decorin can compete with TGF- β for binding to its receptors, TGF- β receptor (TGF- β R)-I and -II [88]. Notably, through interaction with IGF-IR, decorin is able of inducing translation of fibrillin-1, which is a regulator of TGF- β availability (Figure 1) [28, 89]. In renal tubular epithelial cells through IGF-IR signaling cascade decorin leads to

an inhibition of apoptosis [54]. Thus, the mechanism of action is complex and likely mediated by a differential activity of decorin on multiple RTKs.

Recent studies have revealed that decorin's antifibrotic effects may not be limited to its interaction with TGF- β and its receptors. The cysteine-rich cytokine, connective tissue growth factor (CTGF/CCN2) is a downstream mediator of TGF- β signaling [90] and plays an important role in the evolution of fibrotic disease [91, 92]. CTGF is expressed in response to TGF- β in a variety of cell types, including fibroblasts and renal proximal tubule epithelial cells [93], shows mitogenic and chemotactic properties, and induces the synthesis of collagen I, III, integrin β 1 and fibronectin [94].

Remarkably, knockdown of decorin in myoblasts causes increased fibronectin accumulation and sensitivity to CTGF [94]. Concurrently, addition of decorin to CTGF-stimulated myoblasts reduces the levels of collagen III and fibronectin and inhibits actin stress fiber formation. The same inhibitory effect of decorin on CTGF activity can be reproduced in fibroblasts, suggesting that this inhibition could be a general mechanism of CTGF regulation [94]. Indeed, decorin was shown to interact directly with CTGF with high affinity, through LRR12 of its protein core [94]. Moreover, in myoblasts, decorin was shown to be synthesized in response to CTGF. Given the fact that increased CTGF levels are found in renal fibrosis at the sites of tubulointerstitial damage [95], it is likely that decorin/CTGF interaction is key factor, which could provide a mechanistic explanation for the reported antifibrotic properties of this SLRP in renal pathophysiology.

It is puzzling that biglycan, in spite of its shared ability with decorin to bind TGF- β *in vitro* [87], lacks antifibrotic activity in the kidney [57, 74]. Biglycan is synthesized in response to TGF- β in all renal cell types [83, 96–98] and is expressed in the interstitium and glomeruli under fibrotic conditions [79, 96, 97, 99]. While in the healthy kidney, biglycan is most likely eliminated in plasma or proteolytically degraded, in fibrotic disease it accumulates either due to the increased presence of its collagen-binding partners or due to reduced proteolytic degradation [57]. Interestingly, a role for TLR4, which can be activated by biglycan [24], was found in promoting the evolution of renal fibrosis following UUO [100], in contrast to TLR2, which has no effect on fibrosis [101]. Thus, as biglycan levels are increased in fibrotic tissue, it is possible that the observed effects are a consequence of TLR4 activation by biglycan released or de novo synthesized.

Lumican and fibromodulin are both expressed in renal parenchyma, with expression patterns resembling decorin in the case of lumican and biglycan in the case of fibromodulin [57]. Lumican is a component of the endothelial cell surface considered to play a central role in the glomerular barrier [102]. Both lumican and fibromodulin localize to fibrotic regions in diabetic nephropathy [96], though a role for them in the development of renal fibrosis has not yet been reported. However, roles in the development of liver fibrosis for lumican [103], fibromodulin [104] and decorin [105] were recently found. It is therefore likely that lumican and fibromodulin might have similar profibrotic effects in the kidney, and research in this direction would surely provide novel and interesting data.

2.2. SLRPs in renal inflammation and diabetic nephropathy

Several studies have shown that biglycan acts as a proinflammatory danger molecule by signaling through the LRR-containing receptors TLR2 and TLR4 [24, 106–108]. For a comprehensive review of the literature on the subject see our recent publication [60]. Below, we will critically evaluate the main findings regarding the proinflammatory role of biglycan while focusing on its role in kidney inflammatory conditions.

Under conditions of tissue stress or injury biglycan can be released from the extracellular matrix by proteolytic enzymes, such as bone morphogenic protein (BMP)-1, matrix metalloproteinase (MMP)-2, -3 and -13 [58]. Soluble biglycan then binds to TLR2 and TLR4 and activates the mitogen-activated protein kinase p38, extracellular signal-regulated kinase (Erk), and nuclear factor kappa-light-chain enhancer of activated B cells (NF- κ B) pathways, leading to the secretion of tumor necrosis factor (TNF)- α , in a myeloid differentiation primary response 88 (MyD88) dependent fashion [60]. In turn, this leads to the secretion of a series of chemoattractants for T cells, neutrophils and macrophages, including Chemokine (C-X-C motif) ligand 2 (CXCL2), Chemokine (C-C motif) ligand (CCL3), CCL2 and CCL5, with the attracted macrophages further synthesizing biglycan, and amplifying the proinflammatory response [60]. Additionally, biglycan can autonomously engage the activation of the NLR family, pyrin domain-containing 3 (NLRP3) inflammasome, and trigger the activation of caspase-1. Caspase-1, in turn, cleaves pro-interleukin-1 β (pro-IL-1 β) to mature IL-1 β (Figure 1) [106].

In UUO, biglycan is overexpressed in the epithelial cells of distal tubules and collecting ducts, followed by macrophage infiltration [83, 101, 109]. Biglycan-deficient (*Bgn*^{-/-}) mice show lower levels of activated caspase-1 and mature IL-1 β and less renal damage in response to UUO [106]. Biglycan overexpression or accumulation is a feature of several models of kidney disease, such as ischemia/reperfusion injury [110] or chronic renal allograft rejection [111]. In these renal disease models, a genetic background deficient in either TLR2/4 or MyD88 ameliorates the inflammatory phenotype [110, 111]. Notably, administration of rosiglitazone, an agonist of the nuclear receptor peroxisome proliferator-activated receptor (PPAR) gamma, reduces the amount of synthesized biglycan in a rat model of renal transplantation [112]. In addition, administration of rosiglitazone could also block macrophage synthesis of biglycan.

Biglycan is a factor that aggravates experimental lupus nephritis [107], where expression of biglycan positively correlates with expression of CXCL13 and increased albuminuria in Murphy Roths Large (MRL) lupus-prone mice. Moreover, biglycan attracts B- and T-cells to the kidney, by evoking the production of their respective chemoattractants. Consistent with these findings, transient overexpression of circulating soluble biglycan stimulates the expression of CCL2, CCL3 and CCL5 and aggravates the symptoms of murine lupus nephritis. Consequently, biglycan deficiency suppresses disease activity and renal damage [107]. We have recently discovered that transient overexpression of soluble biglycan in mice leads to renal accumulation of biglycan and increased levels of CXCL1, CXCL2, CCL2 and CCL1 [113]. Interestingly, production of CXCL1, CXCL2 and CCL2 occurs through the

MyD88 pathway, while production of CCL5 is TIR-domain-containing adapter-inducing interferon β (TRIF)-dependent [113].

Diabetic nephropathy is a complication of diabetes that is the leading cause of end-stage renal failure [114]. Evidence suggests a role for biglycan signaling in the development of diabetic nephropathy. Biglycan upregulation in the kidney occurs in all stages of diabetic nephropathy [96, 115]. Diabetic mice exhibit elevation of TGF- β and biglycan levels and high renal lipid retention. The retention of lipids is likely due to the synthesis of abnormal biglycan proteoglycan harboring elongated GAG chains in response to TGF- β [115], as it was previously reported that proteoglycans with large GAG chains have an increased affinity towards low-density lipoprotein (LDL) [116].

Decorin, as biglycan, is overexpressed in the tubulointerstitium in diabetic nephropathy [96]. However, it apparently serves a completely different role, as decorin deficiency enhances murine diabetic nephropathy, with diabetic *Dcn*^{-/-} mice showing increased albuminuria, expanded mesangial matrix, impaired renal function and higher levels of macrophage infiltration compared to wild type animals [84].

Decorin is also a ligand of TLR2 and TLR4, and can stimulate the production of proinflammatory molecules [25]. However, proinflammatory effects of decorin have not been so far reported in the kidney. Quite contrarily, a recent study shows a decrease in decorin levels in glomerulonephritides caused by overexpression of the Ovarian-tumor-domain-containing protease OTUB1 [117]. In patients suffering from the most common form of glomerulonephritis, IgA nephropathy, decorin was found to be upregulated in the glomerulus, with a speculated protective role [118]. Human adult renal stem/progenitor cells were shown to promote repair of kidney damage following acute kidney injury, in a process dependent on TLR2, decorin and inhibin-A [119].

The studies summarized above point to a complex regulation of renal fibrosis, with potential compensatory and aggravating mechanisms involving various SLRPs. As we discover new receptors and signaling pathways for SLRPs, we will undoubtedly find this field of research high rewarding and with potential new targets for disease control or cure.

3. SLRPs in lung disease

3.1. Role of SLRPs in asthma

Asthma is a chronic inflammatory disorder of the airways associated with airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness and coughing [120]. As SLRPs control both collagen fibrillogenesis and matrix assembly, it is not surprising that these proteoglycans have been implicated in the pathogenesis of asthma as consequences caused by the alteration in their synthesis, deposition and distribution [121–123]. Earlier studies reported a significantly increased deposition of biglycan and lumican in the subepithelial layer of the airway walls of patients with mild atopic asthma and these changes correlated with increased airway responsiveness [123]. These findings suggest a role for SLRPs in airway wall remodeling and airway mechanics in mild asthma [123]. Indeed, patients with mild asthma present higher biglycan

but lower decorin deposition in bronchial mucosa compared to healthy controls [124]. Moreover, decorin and biglycan, together with hyaluronan and versican, are deposited in airways of patients who died of severe asthma, mainly localized in submucosa and around smooth muscle cells [125]. Another study performed in patients dying of severe asthma could show decreased staining of decorin and lumican but not biglycan in the outer area of small airways in asthmatics compared with controls [126]. Later studies described how SLRPs can be excessively deposited in the subepithelial and airway smooth muscle (ASM) layers in patients suffering from both moderate and severe asthma but the staining pattern differs [121]. Endobronchial biopsies show a prominent staining for biglycan and lumican but not decorin in both mild and severe asthmatic patients compared to healthy controls. The ASM layers presented increased biglycan and lumican in moderate asthma compared to the severe condition while in the subepithelial layers biglycan and lumican abundance is similar under both mild and severe conditions of asthma [121]. Few *in vitro* studies are available showing that fibroblasts from the airway of asthmatic patients present more biglycan and decorin compared to cells isolated from normal controls [127, 128]. Another study shows that while there is an enhanced biglycan production in centrally-derived fibroblasts from asthmatic subjects compared with controls, no difference could be detected in distal airway fibroblasts unless cells were stimulated with TGF- β 1 [129]. Moreover the negative correlation between the alveolar nitric oxide concentration and biglycan production indicates that NO can also reflect the degree of remodeling [129]. In rats, following sensitization to ovalbumin, biglycan and decorin levels are markedly increased in the airway wall, presenting different cellular and subcellular localizations: while biglycan was predominantly detected within the ASM, decorin was detected outside the ASM, in the adventitial layer [130]. The expression changes of the abovementioned SLRPs in asthma as well as their different distribution among the airway layers suggest their potential functional role in asthma [122, 130]. Thus, the composition of the extracellular matrix, which has developed during pulmonary remodeling in asthmatic patients, is complex and diverse in terms of SLRP composition, with no single identifiable pattern.

A pathological feature for asthma is “airway remodeling” characterized by structural changes and thickening of the airway wall [130–132] as a result of permanent inflammation and epithelial damage in response to repetitive injury [133]. A key role in airway remodeling is held by the potential of the ASM cells to modulate and interact with the extracellular matrix environment [134–136]. Besides their different features at the expression level decorin has also functional effects on lung mechanics, inflammation, and airway remodeling in allergic asthma [122]. Ovalbumin-challenged *Dcn*^{-/-} mice present more modest lung hyperresponsiveness vis-à-vis wild type. Moreover, these mice do not have significantly increased tissue inflammation and Th2 cytokine message following ovalbumin challenge compared to wild type mice. Furthermore, decorin deficiency determined the absence of collagen deposition and a reduced degree of airway remodeling due to maybe less inflammation [122]. Given that decorin is able to bind TGF- β 1 and to co-localize with this cytokine in bronchial biopsies from asthmatic patients [131], both modest airway hyperresponsiveness and less inflammation found in ovalbumin-sensitized *Dcn*^{-/-} mice might be attributed to higher TGF- β 1 bioavailability [122]. Notably, also biglycan is increased within the airway wall area in ovalbumin-exposed *Dcn*^{-/-} mice [122]. Given that

biglycan is predominantly detected within the ASM unlike decorin that is localized to the adventitial layer, the increase of biglycan and the absence of decorin could justify the limitation of airway remodeling in ovalbumin-challenged *Dcn*^{-/-} mice [122]. Biglycan localization within the ASM layer and surrounding the ASM bundles themselves might contribute to the limitation of the airway narrowing by conferring parallel elastic impedance or radial constraint to ASM shortening [122, 137]. Additionally, in the case of decorin, its absence causes a better coupling of the airways and parenchyma and an increased remodeling or thickening of the adventitial layer results in reduced transmission of interdependence forces acting against ASM shortening [122, 137]. Furthermore, another study revealed the influence of TGF- β isoforms on OVA-induced decorin deposition in sub-epithelial layer of the airway lumen in mice. Treatment of animals with anti-TGF- β 1 but not with anti-TGF- β 2 inhibits the OVA-induced increase in decorin deposition [138].

An important contributor to asthma airway pathology is the abnormal mechanical strain, which can be sensed by the structural cells of the airway like epithelial cells, fibroblasts and ASM cells [139–141]. A recent study investigated how alterations of biglycan, decorin and collagen and mechanical strain conditions effect the proliferation of the ASM cells isolated from Brown Norway rats challenged with ovalbumin [141]. Both isolated from ovalbumin-sensitized rats or controls, ASM cells seeded on a decorin matrix proliferate slower compared to when they are grown on plastic; the effect was weaker in the case of ovalbumin treated rats. Biglycan has the same effect but only in control cells [141].

3.2. SLRPs in pulmonary infection and sepsis

Pulmonary damage, classified as either acute lung injury or acute respiratory distress syndrome is a common complication and one of the major causes of death following sepsis [142]. The proinflammatory role of biglycan in the progression of sepsis was revealed in one of our earlier studies [24]. Biglycan deficiency improves mouse survival in both LPS- and zymosan-induced sepsis, and reduces the amount of TNF- α in plasma. In wild-type mice, biglycan levels in infiltrating cells of lung parenchyma are increased under septic conditions, as a consequence of biglycan production by macrophages. *In vitro*, exogenous soluble biglycan stimulates macrophages to produce TNF- α and CXCL2, a chemoattractant for macrophages. Consequently, *Bgn*^{-/-} mice have less prevalent immune cell infiltrates in septic lungs [24]. Additionally, biglycan deficiency also lowers levels of mature IL1- β and active caspase-1 in septic lungs, resulting in less organ damage [106].

Interestingly, decorin is also upregulated in septic lungs and decorin deficiency also ameliorates the outcome of sepsis [25]. Levels of the anti-inflammatory cytokine IL-10 are increased, while levels of TNF- α and IL-12 are reduced in septic lungs of *Dcn*^{-/-} mice. Injection of exogenous decorin in *Dcn*^{-/-} mice subjected to sepsis results in lower levels of IL-10 and increased levels of TNF- α and IL-12 in the lung. This proinflammatory effect of decorin is mediated through interaction with TLR2/4 and production of programmed cell death 4 (PDCD4) [25].

Lumican was recently found to have a critical role in the clearance of bacterial infection [143, 144]. *Lum*^{-/-} mice show increased severity of *Pseudomonas aeruginosa* lung infection, manifested by reduced survival and increased pulmonary damage [143]. Lumican

is capable of promoting phagocytosis by associating with the bacterial surface as well as with the adapter protein cluster of differentiation 14 (CD14). In the latter interaction, a critical role is played by Tyr20 of lumican, as mutation of this residue to alanine causes a severely-reduced effect of lumican on phagocytosis [143].

3.3. Role of SLRPs in pulmonary fibrosis and chronic obstructive pulmonary disease

Idiopathic pulmonary fibrosis, the most common fibrotic lung disease, has a 5-year survival rate of only 20%, and has no effective therapy [145]. A widely-used experimental animal of pulmonary fibrosis is based on the use of the cytotoxic drug bleomycin [146]. Intratracheal administration of bleomycin causes an rapid and robust inflammatory response and increased epithelial apoptosis, followed by resolution of inflammation and ECM deposition, forming areas of fibrosis [146].

In rats with bleomycin-induced pulmonary fibrosis there is a dynamic modulation of various SLRPs, with increased levels of biglycan and fibromodulin [147] and reduced levels of decorin [148]. Decorin's antifibrotic effects are also operational in lung fibrosis, where this SLRP might serve as a powerful treatment for this condition. Indeed, bleomycin-induced lung fibrosis in hamsters can be ameliorated by instillation of decorin, with reduction in both the size of the fibrotic lesions and the number of infiltrating neutrophils [149]. Transient expression of decorin using an intranasal-administered adenoviral vector was also reduces the profibrotic effects of bleomycin, without influencing the initial inflammatory response, an effect which was speculated to occur through the inactivation of TGF- β [150]. In a subsequent study, intratracheal administration of an adenoviral vector expressing decorin decreased subpleural fibroproliferation in bleomycin-induced lung fibrosis, while intravenous administration of the same vector had no effect [151]. *In vitro*, transfection of decorin, but not biglycan could block the activity of TGF- β in lung fibroblasts [74]. A similar effect also occurs *in vivo*, where transient overexpression of TGF- β by intranasal injection of an adenoviral vector causes interstitial fibrosis, a process that is significantly attenuated by the concomitant transient expression of decorin, but not biglycan [74]. Thus, decorin delivered as either recombinant proteoglycan or endogenously produced via adenoviral transduction, possesses anti-fibrotic effects. Whether all the effects can be attributed to its TGF- β -blocking ability needs to be further investigated.

Chronic obstructive pulmonary disease (COPD) is an inflammatory airway disease, characterized by progressive and irreversible decline in lung function caused by airflow obstruction, destruction of parenchyma and emphysema [152]. The primary cause of COPD is exposure to air pollutants, primarily cigarette smoke [152]. Airway remodeling is one of the characteristics of COPD; interestingly, in COPD lungs the ECM is degraded in alveoli but increased in bronchi and bronchioles [153]. Early studies pointed out a reduction in the expression of biglycan and decorin in the peribronchiolar area in patients suffering from severe emphysema, associated with increased levels of TGF- β [154]. Additionally, fibroblasts from isolated from patients with severe emphysema showed reduced decorin production in the supernatant in response to TGF- β [155]. However, single nucleotide polymorphisms in the *Dcn* gene were not found to be a risk factor in the development of COPD [156]. As these results differ from those obtained with patients suffering from milder

forms of COPD, where biglycan and decorin levels are not different from controls [136], it is apparent that severe modifications in the ECM occur only in the later stages of COPD.

COPD is characterized by an influx of immune cells in the lung. Interestingly, peripheral blood mononuclear cells isolated from COPD produce higher amounts of anti-decorin IgG in response to stimulation with decorin [157]. Administration of corticosteroids along with bronchodilators such as β_2 agonists is the current treatment method of choice for COPD [158]. Effects of such treatments on SLRP expression show promising results. In an *in vitro* study, fluticasone could induce decorin production by airway fibroblasts from patients with severe COPD, and reverse the negative effects of TGF- β on ECM production in these cells [159]. Additionally, biglycan production is inhibited by fluticasone in both airway and parenchymal fibroblasts. In patients suffering from moderate COPD, administration of corticosteroids increased the density of decorin staining in bronchial tissue [160]. However, treatment with the vasodilator prostacyclin has no effect on biglycan or decorin expression in fibroblasts from COPD patients [161].

3.4. Role of SLRPs in lung cancer

An emerging body of evidence supports the idea that several SLRPs might play a significant role in tumor progression, by affecting both the composition of the tumor stroma as well as the growth of cancer cells [4, 9, 59, 162, 163]. Decorin is the most investigated so far among the SLRPs and represent a potential therapeutic molecule to combat many forms of cancer, particularly due to its ability to interact with many receptor tyrosine kinase (RTKs) and downregulate their activity [163]. Decorin has a potent antitumorigenic effect and is able to repress and attenuate tumor cell proliferation, survival, migration and angiogenesis [59, 164]. It is well known that decorin is able to interact with RTKs including EGFR, Met, ErbB2/4 or vascular endothelial growth factor receptor (VEGFR2) thereby attenuating the respective signaling pathways (Figure 2) [1, 59]. The first RTK revealed to bind decorin in tumor cells was EGFR [27]. Following decorin binding the receptor dimerizes and is further endocytosed via caveolar-mediated pathway, which leads to translocation into caveosomes and eventually to lysosomal degradation [165] (Figure 2). In parallel, following decorin binding and EGFR phosphorylation, ERK1/2 are activated, leading to the transcription of the *CDKN1A* gene corresponding to cyclin-dependent kinase inhibitor 1, p21^{WAF1}, thus ultimately leading to growth suppression [163, 166] (Figure 2). Another effect downstream of decorin-mediated EGFR phosphorylation is the activation of caspase-3, which in turn cleaves the intracellular domain of EGFR [167].

Decorin interferes with the Met signaling pathway causing down-regulation and shedding of Met, attenuation of the signaling effects and inhibition of tumor growth [36, 37, 162]. When Wnt or RTK pathways (EGFR or Met) are activated, Myc is phosphorylated at Serine 62 (S62), triggering translocation of Myc to the nucleus where the synthesis of activating enhancer-binding protein (AP4) is induced [162]. AP4 is a transcriptional repressor of *CDKN1A* gene [168] (Figure 2). At the same time, β -catenin is translocated to the nucleus where it is recruited to and activates lymphoid enhancer-binding factor/T-cell-specific factor (TCF/LEF)-related gene transcription [35, 169]. The synthesis of tumor-associated genes such as c-MYC and MYCN is then induced [162] (Figure 2). When decorin binds to Met,

the above-mentioned pathways are inhibited. Myc is phosphorylated at Threonine 58 (T58), known to destabilize Myc and target it for proteasomal degradation [37] (Figure 2). The consequent effects are suppression of cell motility, migration and tumor growth, both *in vitro* and *in vivo* [37]. Thus, at least for decorin/Met interaction a partial mechanism has been elucidated. We predict that other SLRPs would also interact with other members of this large RTK family and that these interactions would be important in the pathophysiology of pulmonary and renal diseases.

Decorin is known to play an important role in tumor angiogenesis but its influence in this process is still remaining to be investigated taking into consideration data advocating for both proangiogenic and antiangiogenic roles [162]. However, the studies revealing the proangiogenic role of decorin are described mostly in non-tumorigenic cells [59, 170]. Decorin was proved as an angiostatic agent in tumor cells via down-regulation of vascular endothelial growth factor (VEGF) [171]. Recently, Neill et al. observed by PCR array in HeLa cells under normoxia conditions that decorin inhibits the transcription of pro-angiogenic genes including *MET*, hypoxia inducible factor-1 α , *HIF1A*, and *VEGFA* while upregulating the transcription of anti-angiogenic genes such as metalloproteinase inhibitor 3, *TIMP3* and thrombospondin 1, *THBS1* [172]. Further, the same study reveals that in MDA-MD-231 breast carcinoma cells expressing constitutively active HIF-1 α , decorin reduces the levels of HIF-1 α and *VEGFA* via the Met receptor [172]. In parallel, exogenous decorin triggers the overexpression of angiostatic thrombospondin 1 (TSP-1) and *TIMP3* while inhibiting the expression and activity of pro-angiogenic MMP-9 and MMP-2 [172]. Notably, decorin evokes the rapid release of TSP-1 from quiescent MDA-MB-231 breast carcinoma cells [173]. TSP-1 release is dependent on EGFR signaling, but independent of Met signaling. The mechanism involves the degradation of Ras homolog gene family member A (RhoA) and subsequent inactivation of Rho-associated coiled-coil containing protein kinase 1 (ROCK1) [173].

Recent studies have shown that soluble decorin induces autophagy in human umbilical vein endothelial cells (HUVEC) and in mouse microvascular dermal endothelial cells (MDEC) [26]. At the same time decorin induces the expression of paternally expressed gene 3 (Peg3), which is known as a tumor suppressor, as well as the Peg3-dependent expression of autophagy-related genes *BECN1* and *MAP1LC3a*. In addition, decorin evokes intracytoplasmic colocalization of Peg3, Beclin 1 and LC3 within newly-formed autophagosomes [26]. It was shown that the mechanism was downstream of decorin binding to VEGFR2 (Figure 2)[174]. As a consequence decorin inhibits capillary morphogenesis and endothelial cell migration [26]. Thus, decorin, and perhaps other members of the SLRP family, modulate angiogenesis by evoking a biological process such as autophagy, which could lead to angiostasis.

In bladder cancer cells, decorin binds to IGF-IR and to its ligand IGF-I at different binding sites and differently to EGFR and Met, decorin negatively regulates IGF-I-dependent IGF-IR phosphorylation without affecting receptor protein levels [175]. Downstream of IGF-IR activation the recruitment of insulin receptor substrate 1 (IRS-1) to the receptor is required in order to activate the phosphatidylinositide 3-kinase (PI3K) and Akt pathways, promoting cell proliferation and transformation in normal cells [175]. It has been shown that IGF-I acts

as a “scatter factor” in urothelial cancer cells which enhances cell motility and invasion but not cell proliferation [176]. Decorin enhances IGF-I-dependent IRS-1 downregulation upon chronic IGF-I stimulation of tumor cells. It could also inhibit the IGF-I ability to promote migration, lateral motility and invasiveness in cancer cells. Mechanistically, decorin is able to attenuate IGF-I-induced Akt and Erk1/2 pathways and inhibit the downstream targets p70S6K and p90RSK, respectively [175].

Another mechanism was recently proposed regarding the capability of decorin to link inflammation and cancer growth [25]. As previously mentioned in section 3.2, decorin is able to bind TLR2/4 activating Erk and p38 and inducing the transcription of the TNF, interleukin 12B, IL12B, interleukin 10, IL10 and PDCD4 genes (Figure 2). Decorin- or LPS-induced PDCD4 leads to translational repression of IL-10, an anti-inflammatory cytokine (Figure 2). LPS induces active TGF- β 1 production that, by signaling through its receptor, promotes the processing of pri-miR-21 to pre-miR-21 and increases the abundance of mature miR-21, a posttranscriptional inhibitor of PDCD4. By inhibiting TGF- β signaling, decorin decreases the abundance of oncogenic microRNA-21 (miR-21) and prevents the miR-21-dependent translational repression of PDCD4 and thus reduces the levels of IL-10 protein [25] (Figure 2). In the presence of LPS, decorin stimulates the expression of PDCD4 through TLR2 and inhibits the LPS-induced activity of TGF- β 1. Tumor xenografts overexpressing decorin presents an induced proinflammatory immune response through inhibition of TGF- β 1, down-regulation of miR-21, and increased PDCD4 abundance [25]. Notably, these findings were independently confirmed by a recent study demonstrating that decorin can be cleaved by matrix metalloproteinase 8 (MMP-8) and lead to a reduction in tumor growth and lung metastasis formation by MDA-MB-231 (4175) breast cancer cells by inhibiting TGF- β signaling and reducing miR-21 levels [177].

The anti-tumoral effects of decorin in lung cancer were already emphasized in earlier studies showing that in patients with T1 pulmonary adenocarcinoma, TGF- β 1 is primarily associated with central fibrosis [178]. Additionally, when central fibrosis was composed of proliferative connective tissue with weak staining for decorin, cancer cells showed intense staining for TGF- β 1 while when central fibrosis was composed of old fibrotic tissue with dense staining for decorin, cancer cells showed weak staining for TGF- β 1 suggesting the role of decorin as a TGF- β 1 negative regulator in pulmonary adenocarcinoma [178]. Decorin is underexpressed by at least 50% of human lung adenocarcinomas and squamous cell carcinomas [179]. A role for decorin in suppressing pulmonary metastasis from osteosarcoma has also been proposed [180]. Specifically, murine osteosarcoma cells stably expressing decorin are less metastatic than wild-type cells; moreover, *de novo* decorin expression significantly improved the survival of the mice [180]. This study brings into light the potential role of decorin as a novel biological tool for the treatment of pulmonary metastasis [180].

Recently, biglycan has also been found to be abnormally expressed in a number of human tumors such as endometrial [181], pancreatic a [182], gastric [183], colorectal [184], adenomatoid odontogenic tumor [185] and ovarian [186] cancer. However, the mechanisms through which biglycan is involved in tumor progression are far from being clear. Interestingly, TGF- β induces biglycan expression in HFL, HFFF2 fibroblasts and the

pancreatic cancer cell line PANC-1 [187]. Biglycan in turn is able to inhibit growth of TGF- β responsive pancreatic cancer cells by inducing G1-arrest [187]. The biglycan-mediated inhibition of cell growth is accompanied by an increase of p27 and reduction of cyclin A and proliferating cell nuclear antigen, PCNA. Furthermore, endogenous Ras and Erk activation is partly reduced by biglycan *in vitro* [187]. Additionally, an *in vitro* study using oncogene transformation has shown a down-regulation of biglycan expression in both murine and human HER-2/neu oncogene-transformed cells when compared with HER-2/neu(-) cells [188]. Biglycan expression correlates well with reduced growth, wound closure, and migration properties. Biglycan expression was found to be dependent on the protein kinase C (PKC) and cAMP response element binding protein (CREB) [188].

Moreover, biglycan acts as a proangiogenic factor in murine tumor endothelial cells influencing their migration and morphology. Biglycan-induced migration and tube formation is blocked by anti-TLR2 and anti-TLR4 antibodies in biglycan deficient tumor endothelial cells [189]. Additionally, biglycan immunoreactivity is stronger in tumor vessels of patients with colon, lung or liver cancers vis-a-vis healthy patients [189]. Given its role in the development and progression of human cancers and its different expression pattern in different tumors, biglycan could be further evaluated as a biomarker for predicting clinical outcome.

Lumican has also been broadly investigated in cancer with results pointing to an antagonistic role of cancer growth and angiogenesis [162]. However, there are studies that either attribute to lumican a pro-oncogenic agent (in colorectal, pancreatic and lung cancer) as well as that of an anti-oncogenic agent (in osteosarcoma or melanoma) [59, 162]. Mechanistically, similarly to decorin, lumican is a soluble tumor suppressor agent that induces p21^{WAF1} and growth inhibition [190]. In mouse embryonic fibroblasts, lumican-mediated p21^{WAF1} induction depends on the p53 pathway and leads to suppression of cyclins A, D1 and E [162, 191]. At the same time lumican inhibits cell proliferation and is pro-apoptotic through Fas receptor (CD95)-Fas ligand in cornea [191]. Lumican protein core binds the $\alpha 2$ I domain of the $\alpha 2\beta 1$ integrin receptor in melanoma cells, thereby inhibiting cell migration [32]. Notably, *Lum*^{-/-} mice harboring pancreatic adenocarcinomas develop higher volume size tumors and exhibit elevated vascular densities compared to wild-type mice [192]. However, lumican inhibits tumor growth and lung metastasis but not angiogenesis in a 4T1 breast cancer model [192].

A recent study described the importance of lumican in patients with lung cancer. Specifically, lumican is >2-fold upregulated in lung cancer patients compared to healthy subjects using proteomic analysis of serum from lung cancer patients and healthy volunteers [193]. Analysis of the expression of lumican in two types of non-small cell lung cancer revealed different expression patterns. In lung adenocarcinoma, higher levels of lumican could be found in stromal, rather than cancer cells [194]. Contrary to this pattern, in lung squamous cell carcinoma, expression of lumican is higher in cancer cells. [194]. Notably, mice intravenously injected with lumican-expressing B16F1 melanoma cells exhibit a decreased number and size of pulmonary metastases and an increase in tumor cell apoptosis when compared to Mock-B16F1 cells-injected mice [195]. In contrast, however, the levels of VEGF and the number of blood vessels within the lung metastases were decreased

following lumican overexpression [195]. Thus, the roles of SLRPs in lung cancer are quite complex and require additional experimental research to decipher the specific signaling pathways that could affect the behavior of both primary tumor cells and their microenvironment.

4. Conclusion and future perspectives

A large volume of studies now exists on the roles of SLRPs in the pathogenesis and even treatment of pulmonary and renal diseases. It is, however, likely that our knowledge so far is only a small glimpse into the multitude of functions that these molecules have. Most of the available data is restricted to biglycan and decorin, with more interacting partners and signaling pathways discovered every year. Perhaps the most remarkable conclusion of these studies is that decorin has the potential to be a powerful antifibrotic and antitumoral agent, and we anticipate that its value will be appreciated in clinical trials.

However, it is regrettable that research on the other SLRPs is lacking. While there are a number of studies dealing with lumican and fibromodulin, there are several other SLRPs that have been investigated only in few published studies in spite of their widespread distribution and regulated developmental expression. Recent studies on lumican, for example, have shown that it also has antitumoral roles, and further research in this direction is worth considering. We believe that given the current knowledge of SLRP biology, future discoveries are on the horizon and could lead to fundamental changes in our understanding of SLRP function and their involvement in various human pathologies.

Acknowledgments

Original research on SLRP biology in the authors' laboratories was supported by the German Research Council (SFB 815, project A5, SFB 1039, project B2, Excellence Cluster ECCPS to L.S., and GRK1172 to M.V.N. and L.S.), LOEWE program Ub-Net (L.S.) and by National Institutes of Health grants RO1 CA39481, RO1 CA47282 and RO1 CA164462 (R.V.I.). We apologize to those researchers whose work could not be cited due to space limitation.

Abbreviations

AMPK	5' adenosine monophosphate-activated protein kinase
ASM	airway smooth muscle
CCL	Chemokine (C-C motif) ligand
CDKN1A	cyclin-dependent kinase inhibitor 1
COPD	chronic obstructive pulmonary disease
CREB	cAMP response element binding protein
CS	chondroitin sulfate
CTGF/CCN2	connective tissue growth factor
CXCL	Chemokine (C-X-C motif) ligand
DS	dermatan sulfate

ECM	extracellular matrix
EGFR	epidermal growth factor receptor
Erk	extracellular signal-regulated kinase
HIF-1α	hypoxia inducible factor-1 α
IGF-IR	insulin-like growth factor receptor
KS	keratan sulfate
LRR	leucine-rich repeats
miR-21	microRNA-21
MMP	matrix metalloproteinase
p21^{WAF1}	cyclin-dependent kinase inhibitor 1
PDCD4	programmed cell death 4
Peg3	paternally expressed gene 3
RTK	receptor tyrosine kinases
SLRP	small leucine-rich proteoglycan
TGF-β	transforming growth factor β
TGF-βR	TGF- β receptor
TLR	Toll-like receptor
TNF	tumor necrosis factor
TSP-1	thrombospondin 1
VEGFR	vascular endothelial growth factor receptor

References

1. Schaefer L, Iozzo RV. Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. *J Biol Chem.* 2008; 283:21305–21309. [PubMed: 18463092]
2. Hocking AM, Shinomura T, McQuillan DJ. Leucine-rich repeat glycoproteins of the extracellular matrix. *Matrix Biol.* 1998; 17:1–19. [PubMed: 9628249]
3. Park H, Huxley-Jones J, Boot-Handford RP, Bishop PN, Attwood TK, Bella J. LRRCE: a leucine-rich repeat cysteine capping motif unique to the chordate lineage. *BMC Genomics.* 2008; 9:599. [PubMed: 19077264]
4. Iozzo RV, Schaefer L. Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. *FEBS J.* 2010; 277:3864–3875. [PubMed: 20840584]
5. Nikitovic D, Aggelidakis J, Young MF, Iozzo RV, Karamanos NK, Tzanakakis GN. The biology of small leucine-rich proteoglycans in bone pathophysiology. *J Biol Chem.* 2012; 287:33926–33933. [PubMed: 22879588]
6. Chen S, Birk DE. The regulatory roles of small leucine-rich proteoglycans in extracellular matrix assembly. *FEBS J.* 2013; 280:2120–2137. [PubMed: 23331954]
7. Iozzo RV. The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. *J Biol Chem.* 1999; 274:18843–18846. [PubMed: 10383378]

8. Schaefer L, Schaefer RM. Proteoglycans: from structural compounds to signaling molecules. *Cell Tissue Res.* 2010; 339:237–246. [PubMed: 19513755]
9. Schaefer L, Iozzo RV. Small leucine-rich proteoglycans, at the crossroad of cancer growth and inflammation. *Curr Opin Genet Dev.* 2012; 22:56–57. [PubMed: 22326829]
10. Imai K, Hiramatsu A, Fukushima D, Pierschbacher MD, Okada Y. Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. *Biochem J.* 1997; 322(Pt 3):809–814. [PubMed: 9148753]
11. Boivin WA, Shackelford M, Vanden Hoek A, Zhao H, Hackett TL, Knight DA, Granville DJ. Granzyme B cleaves decorin, biglycan and soluble betaglycan, releasing active transforming growth factor-beta1. *PLoS ONE.* 2012; 7:e33163. [PubMed: 22479366]
12. Heathfield TF, Onnerfjord P, Dahlberg L, Heinegard D. Cleavage of fibromodulin in cartilage explants involves removal of the N-terminal tyrosine sulfate-rich region by proteolysis at a site that is sensitive to matrix metalloproteinase-13. *J Biol Chem.* 2004; 279:6286–6295. [PubMed: 14660626]
13. Melching LI, Fisher WD, Lee ER, Mort JS, Roughley PJ. The cleavage of biglycan by aggrecanases. *Osteoarthritis Cartilage.* 2006; 14:1147–1154. [PubMed: 16806997]
14. Fleischmajer R, Fisher LW, MacDonald ED, Jacobs L Jr, Perlish JS, Termine JD. Decorin interacts with fibrillar collagen of embryonic and adult human skin. *J Struct Biol.* 1991; 106:82–90. [PubMed: 2059554]
15. Svensson L, Heinegard D, Oldberg A. Decorin-binding sites for collagen type I are mainly located in leucine-rich repeats 4–5. *J Biol Chem.* 1995; 270:20712–20716. [PubMed: 7657652]
16. Douglas T, Heinemann S, Bierbaum S, Scharnweber D, Worch H. Fibrillogenesis of collagen types I, II, and III with small leucine-rich proteoglycans decorin and biglycan. *Biomacromolecules.* 2006; 7:2388–2393. [PubMed: 16903686]
17. Wiberg C, Hedbom E, Khairullina A, Lamande SR, Oldberg A, Timpl R, Morgelin M, Heinegard D. Biglycan and decorin bind close to the n-terminal region of the collagen VI triple helix. *J Biol Chem.* 2001; 276:18947–18952. [PubMed: 11259413]
18. Schonherr E, Witsch-Prehm P, Harrach B, Robenek H, Rauterberg J, Kresse H. Interaction of biglycan with type I collagen. *J Biol Chem.* 1995; 270:2776–2783. [PubMed: 7852349]
19. Svensson L, Narlid I, Oldberg A. Fibromodulin and lumican bind to the same region on collagen type I fibrils. *FEBS Lett.* 2000; 470:178–182. [PubMed: 10734230]
20. Kalamajski S, Aspberg A, Lindblom K, Heinegard D, Oldberg A. Asporin competes with decorin for collagen binding, binds calcium and promotes osteoblast collagen mineralization. *Biochem J.* 2009; 423:53–59. [PubMed: 19589127]
21. Markmann A, Hausser H, Schonherr E, Kresse H. Influence of decorin expression on transforming growth factor-beta-mediated collagen gel retraction and biglycan induction. *Matrix Biol.* 2000; 19:631–636. [PubMed: 11102752]
22. Sanders EJ, Walter MA, Parker E, Aramburo C, Harvey S. Opticin binds retinal growth hormone in the embryonic vitreous. *Invest Ophthalmol Vis Sci.* 2003; 44:5404–5409. [PubMed: 14638744]
23. Embree MC, Kilts TM, Ono M, Inkson CA, Syed-Picard F, Karsdal MA, Oldberg A, Bi Y, Young MF. Biglycan and fibromodulin have essential roles in regulating chondrogenesis and extracellular matrix turnover in temporomandibular joint osteoarthritis. *Am J Pathol.* 2010; 176:812–826. [PubMed: 20035055]
24. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, Krzyzankova M, Marsche G, Young MF, Mihalik D, Gotte M, Malle E, Schaefer RM, Grone HJ. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. *J Clin Invest.* 2005; 115:2223–2233. [PubMed: 16025156]
25. Merline R, Moreth K, Beckmann J, Nastase MV, Zeng-Brouwers J, Tralhao JG, Lemarchand P, Pfeilschifter J, Schaefer RM, Iozzo RV, Schaefer L. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. *Sci Signal.* 2011; 4:ra75. [PubMed: 22087031]
26. Buraschi S, Neill T, Goyal A, Poluzzi C, Smythies J, Owens RT, Schaefer L, Torres A, Iozzo RV. Decorin causes autophagy in endothelial cells via Peg3. *Proc Natl Acad Sci U S A.* 2013; 110:E2582–2591. [PubMed: 23798385]

27. Iozzo RV, Moscatello DK, McQuillan DJ, Eichstetter I. Decorin is a biological ligand for the epidermal growth factor receptor. *J Biol Chem.* 1999; 274:4489–4492. [PubMed: 9988678]
28. Schaefer L, Tsalastra W, Babelova A, Baliova M, Minnerup J, Sorokin L, Grone HJ, Reinhardt DP, Pfeilschifter J, Iozzo RV, Schaefer RM. Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and Mammalian target of rapamycin. *Am J Pathol.* 2007; 170:301–315. [PubMed: 17200203]
29. D'Onofrio MF, Brezillon S, Baranek T, Perreau C, Roughley PJ, Maquart FX, Wegrowski Y. Identification of beta1 integrin as mediator of melanoma cell adhesion to lumican. *Biochem Biophys Res Commun.* 2008; 365:266–272. [PubMed: 17981144]
30. Guidetti G, Bertoni A, Viola M, Tira E, Balduini C, Torti M. The small proteoglycan decorin supports adhesion and activation of human platelets. *Blood.* 2002; 100:1707–1714. [PubMed: 12176891]
31. Fiedler LR, Schonherr E, Waddington R, Niland S, Seidler DG, Aeschlimann D, Eble JA. Decorin regulates endothelial cell motility on collagen I through activation of insulin-like growth factor I receptor and modulation of alpha2beta1 integrin activity. *J Biol Chem.* 2008; 283:17406–17415. [PubMed: 18413316]
32. Zeltz C, Brezillon S, Kapyla J, Eble JA, Bobichon H, Terryn C, Perreau C, Franz CM, Heino J, Maquart FX, Wegrowski Y. Lumican inhibits cell migration through alpha2beta1 integrin. *Exp Cell Res.* 2010; 316:2922–2931. [PubMed: 20705068]
33. Niewiarowska J, Brezillon S, Sacewicz-Hofman I, Bednarek R, Maquart FX, Malinowski M, Wiktorska M, Wegrowski Y, Cierniewski CS. Lumican inhibits angiogenesis by interfering with alpha2beta1 receptor activity and downregulating MMP-14 expression. *Thromb Res.* 2011; 128:452–457. [PubMed: 21752432]
34. Brandan E, Retamal C, Cabello-Verrugio C, Marzolo MP. The low density lipoprotein receptor-related protein functions as an endocytic receptor for decorin. *J Biol Chem.* 2006; 281:31562–31571. [PubMed: 16936287]
35. Berendsen AD, Fisher LW, Kilts TM, Owens RT, Robey PG, Gutkind JS, Young MF. Modulation of canonical Wnt signaling by the extracellular matrix component biglycan. *Proc Natl Acad Sci U S A.* 2011; 108:17022–17027. [PubMed: 21969569]
36. Goldoni S, Humphries A, Nystrom A, Sattar S, Owens RT, McQuillan DJ, Ireton K, Iozzo RV. Decorin is a novel antagonistic ligand of the Met receptor. *J Cell Biol.* 2009; 185:743–754. [PubMed: 19433454]
37. Buraschi S, Pal N, Tyler-Rubinstein N, Owens RT, Neill T, Iozzo RV. Decorin antagonizes Met receptor activity and down-regulates {beta}-catenin and Myc levels. *J Biol Chem.* 2010; 285:42075–42085. [PubMed: 20974860]
38. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, Iozzo RV. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. *J Cell Biol.* 1997; 136:729–743. [PubMed: 9024701]
39. Reed CC, Iozzo RV. The role of decorin in collagen fibrillogenesis and skin homeostasis. *Glycoconj J.* 2002; 19:249–255. [PubMed: 12975602]
40. Zhang G, Chen S, Goldoni S, Calder BW, Simpson HC, Owens RT, McQuillan DJ, Young MF, Iozzo RV, Birk DE. Genetic evidence for the coordinated regulation of collagen fibrillogenesis in the cornea by decorin and biglycan. *J Biol Chem.* 2009; 284:8888–8897. [PubMed: 19136671]
41. Schonherr E, Sunderkotter C, Schaefer L, Thanos S, Grassel S, Oldberg A, Iozzo RV, Young MF, Kresse H. Decorin deficiency leads to impaired angiogenesis in injured mouse cornea. *J Vasc Res.* 2004; 41:499–508. [PubMed: 15528932]
42. Fust A, LeBellego F, Iozzo RV, Roughley PJ, Ludwig MS. Alterations in lung mechanics in decorin-deficient mice. *Am J Physiol Lung Cell Mol Physiol.* 2005; 288:L159–166. [PubMed: 15447936]
43. Bi X, Tong C, Dockendorff A, Bancroft L, Gallagher L, Guzman G, Iozzo RV, Augenlicht LH, Yang W. Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. *Carcinogenesis.* 2008; 29:1435–1440. [PubMed: 18550571]
44. Xu T, Bianco P, Fisher LW, Longenecker G, Smith E, Goldstein S, Bonadio J, Boskey A, Heegaard AM, Sommer B, Satomura K, Dominguez P, Zhao C, Kulkarni AB, Robey PG, Young

- MF. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. *Nat Genet.* 1998; 20:78–82. [PubMed: 9731537]
45. Ameye L, Aria D, Jepsen K, Oldberg A, Xu T, Young MF. Abnormal collagen fibrils in tendons of biglycan/fibromodulin-deficient mice lead to gait impairment, ectopic ossification, and osteoarthritis. *FASEB J.* 2002; 16:673–680. [PubMed: 11978731]
 46. Corsi A, Xu T, Chen XD, Boyde A, Liang J, Mankani M, Sommer B, Iozzo RV, Eichstetter I, Robey PG, Bianco P, Young MF. Phenotypic effects of biglycan deficiency are linked to collagen fibril abnormalities, are synergized by decorin deficiency, and mimic Ehlers-Danlos-like changes in bone and other connective tissues. *J Bone Miner Res.* 2002; 17:1180–1189. [PubMed: 12102052]
 47. Bi Y, Stuelten CH, Kilts T, Wadhwa S, Iozzo RV, Robey PG, Chen XD, Young MF. Extracellular matrix proteoglycans control the fate of bone marrow stromal cells. *J Biol Chem.* 2005; 280:30481–30489. [PubMed: 15964849]
 48. Ameye L, Young MF. Mice deficient in small leucine-rich proteoglycans: novel in vivo models for osteoporosis, osteoarthritis, Ehlers-Danlos syndrome, muscular dystrophy, and corneal diseases. *Glycobiology.* 2002; 12:107R–116R.
 49. Goldberg M, Ono M, Septier D, Bonnefoix M, Kilts TM, Bi Y, Embree M, Ameye L, Young MF. Fibromodulin-deficient mice reveal dual functions for fibromodulin in regulating dental tissue and alveolar bone formation. *Cells Tissues Organs.* 2009; 189:198–202. [PubMed: 18698127]
 50. Zheng Z, Nguyen C, Zhang X, Khorasani H, Wang JZ, Zara JN, Chu F, Yin W, Pang S, Le A, Ting K, Soo C. Delayed wound closure in fibromodulin-deficient mice is associated with increased TGF-beta3 signaling. *J Invest Dermatol.* 2011; 131:769–778. [PubMed: 21191417]
 51. Chakravarti S. Functions of lumican and fibromodulin: lessons from knockout mice. *Glycoconj J.* 2002; 19:287–293. [PubMed: 12975607]
 52. Liu CY, Birk DE, Hassell JR, Kane B, Kao WW. Keratocan-deficient mice display alterations in corneal structure. *J Biol Chem.* 2003; 278:21672–21677. [PubMed: 12665512]
 53. Nuka S, Zhou W, Henry SP, Gendron CM, Schultz JB, Shinomura T, Johnson J, Wang Y, Keene DR, Ramirez-Solis R, Behringer RR, Young MF, Hook M. Phenotypic characterization of epiphycan-deficient and epiphycan/biglycan double-deficient mice. *Osteoarthritis Cartilage.* 2010; 18:88–96. [PubMed: 19932218]
 54. Merline R, Schaefer RM, Schaefer L. The matricellular functions of small leucine-rich proteoglycans (SLRPs). *J Cell Commun Signal.* 2009; 3:323–335. [PubMed: 19809894]
 55. Kalamajski S, Oldberg A. The role of small leucine-rich proteoglycans in collagen fibrillogenesis. *Matrix Biol.* 2010; 29:248–253. [PubMed: 20080181]
 56. Theocharis AD, Skandalis SS, Tzanakakis GN, Karamanos NK. Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. *FEBS J.* 2010; 277:3904–3923. [PubMed: 20840587]
 57. Schaefer L. Small leucine-rich proteoglycans in kidney disease. *J Am Soc Nephrol.* 2011; 22:1200–1207. [PubMed: 21719787]
 58. Moreth K, Iozzo RV, Schaefer L. Small leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation. *Cell Cycle.* 2012; 11:2084–2091. [PubMed: 22580469]
 59. Neill T, Schaefer L, Iozzo RV. Decorin: a guardian from the matrix. *Am J Pathol.* 2012; 181:380–387. [PubMed: 22735579]
 60. Nastase MV, Young MF, Schaefer L. Biglycan: a multivalent proteoglycan providing structure and signals. *J Histochem Cytochem.* 2012; 60:963–975. [PubMed: 22821552]
 61. Frey H, Schroeder N, Manon-Jensen T, Iozzo RV, Schaefer L. Biological interplay between proteoglycans and their innate immune receptors in inflammation. *FEBS J.* 2013; 280:2165–2179. [PubMed: 23350913]
 62. Pierson DJ. Respiratory considerations in the patient with renal failure. *Respir Care.* 2006; 51:413–422. [PubMed: 16563195]
 63. Lee HY, Stretton TB, Barnes AM. The lungs in renal failure. *Thorax.* 1975; 30:46–53. [PubMed: 235802]
 64. Koynier JL, Murray PT. Mechanical ventilation and lung-kidney interactions. *Clin J Am Soc Nephrol.* 2008; 3:562–570. [PubMed: 18256378]

65. Yap SC, Lee HT. Acute kidney injury and extrarenal organ dysfunction: new concepts and experimental evidence. *Anesthesiology*. 2012; 116:1139–1148. [PubMed: 22415388]
66. Boor P, Sebekova K, Ostendorf T, Floege J. Treatment targets in renal fibrosis. *Nephrol Dial Transplant*. 2007; 22:3391–3407. [PubMed: 17890247]
67. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. *Kidney Int*. 2006; 69:213–217. [PubMed: 16408108]
68. Liang J, Tian S, Han J, Xiong P. Resveratrol as a therapeutic agent for renal fibrosis induced by unilateral ureteral obstruction. *Ren Fail*. 2013
69. Ghayur A, Margetts PJ. Transforming growth factor-beta and the glomerular filtration barrier. *Kidney Res Clin Pract*. 2013; 32:3–10. [PubMed: 23946930]
70. Choi ME, Ding Y, Kim SI. TGF-beta signaling via TAK1 pathway: role in kidney fibrosis. *Semin Nephrol*. 2012; 32:244–252. [PubMed: 22835455]
71. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. *Nature*. 1990; 346:281–284. [PubMed: 2374594]
72. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, Ruoslahti E. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. *Nature*. 1992; 360:361–364. [PubMed: 1280332]
73. Brandan E, Cabello-Verrugio C, Vial C. Novel regulatory mechanisms for the proteoglycans decorin and biglycan during muscle formation and muscular dystrophy. *Matrix Biol*. 2008; 27:700–708. [PubMed: 18694824]
74. Kolb M, Margetts PJ, Sime PJ, Gauldie J. Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. *Am J Physiol Lung Cell Mol Physiol*. 2001; 280:L1327–1334. [PubMed: 11350814]
75. Alan C, Kocoglu H, Altintas R, Alici B, Resit Ersay A. Protective effect of decorin on acute ischaemia-reperfusion injury in the rat kidney. *Archives of medical science : AMS*. 2011; 7:211–216. [PubMed: 22291758]
76. Al Haj Zen A, Caligiuri G, Sainz J, Lemitre M, Demerens C, Lafont A. Decorin overexpression reduces atherosclerosis development in apolipoprotein E-deficient mice. *Atherosclerosis*. 2006; 187:31–39. [PubMed: 16183063]
77. Jarvinen TA. Design of target-seeking antifibrotic compounds. *Methods Enzymol*. 2012; 509:243–261. [PubMed: 22568909]
78. Bianco P, Fisher LW, Young MF, Termine JD, Robey PG. Expression and localization of the two small proteoglycans biglycan and decorin in developing human skeletal and non-skeletal tissues. *J Histochem Cytochem*. 1990; 38:1549–1563. [PubMed: 2212616]
79. Schaefer L, Hausser H, Altenburger M, Ugorcakova J, August C, Fisher LW, Schaefer RM, Kresse H. Decorin, biglycan and their endocytosis receptor in rat renal cortex. *Kidney Int*. 1998; 54:1529–1541. [PubMed: 9844129]
80. Stokes MB, Hudkins KL, Zaharia V, Taneda S, Alpers CE. Up-regulation of extracellular matrix proteoglycans and collagen type I in human crescentic glomerulonephritis. *Kidney Int*. 2001; 59:532–542. [PubMed: 11168935]
81. Mogyrosi A, Ziyadeh FN. What is the role of decorin in diabetic kidney disease? *Nephrol Dial Transplant*. 1999; 14:1078–1081. [PubMed: 10344340]
82. Suzuki K, Wang R, Kubota H, Shibuya H, Saegusa J, Sato T. Kinetics of biglycan, decorin and thrombospondin-1 in mercuric chloride-induced renal tubulointerstitial fibrosis. *Exp Mol Pathol*. 2005; 79:68–73. [PubMed: 16005714]
83. Schaefer L, Macakova K, Raslik I, Micegova M, Grone HJ, Schonherr E, Robenek H, Echtermeyer FG, Grassel S, Bruckner P, Schaefer RM, Iozzo RV, Kresse H. Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. *Am J Pathol*. 2002; 160:1181–1191. [PubMed: 11891213]
84. Williams KJ, Qiu G, Usui HK, Dunn SR, McCue P, Bottinger E, Iozzo RV, Sharma K. Decorin deficiency enhances progressive nephropathy in diabetic mice. *Am J Pathol*. 2007; 171:1441–1450. [PubMed: 17884968]
85. Merline R, Lazaroski S, Babelova A, Tsalastra-Greul W, Pfeilschifter J, Schluter KD, Gunther A, Iozzo RV, Schaefer RM, Schaefer L. Decorin deficiency in diabetic mice: aggravation of

- nephropathy due to overexpression of profibrotic factors, enhanced apoptosis and mononuclear cell infiltration. *J Physiol Pharmacol.* 2009; 60(Suppl 4):5–13. [PubMed: 20083846]
86. Sun JY, Sun Y, Wu HJ, Zhang HX, Zhao ZH, Chen Q, Zhang ZG. Transgene therapy for rat anti-Thy1.1 glomerulonephritis via mesangial cell vector with a polyethylenimine/decorin nanocomplex. *Nanoscale research letters.* 2012; 7:451. [PubMed: 22876812]
 87. Hildebrand A, Romaris M, Rasmussen LM, Heinegard D, Twardzik DR, Border WA, Ruoslahti E. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. *Biochem J.* 1994; 302(Pt 2):527–534. [PubMed: 8093006]
 88. Droguett R, Cabello-Verrugio C, Riquelme C, Brandan E. Extracellular proteoglycans modify TGF-beta bio-availability attenuating its signaling during skeletal muscle differentiation. *Matrix Biol.* 2006; 25:332–341. [PubMed: 16766169]
 89. Schaefer L, Mihalik D, Babelova A, Krzyzankova M, Grone HJ, Iozzo RV, Young MF, Seidler DG, Lin G, Reinhardt DP, Schaefer RM. Regulation of fibrillin-1 by biglycan and decorin is important for tissue preservation in the kidney during pressure-induced injury. *Am J Pathol.* 2004; 165:383–396. [PubMed: 15277214]
 90. Brigstock DR. Connective tissue growth factor (CCN2, CTGF) and organ fibrosis: lessons from transgenic animals. *J Cell Commun Signal.* 2010; 4:1–4. [PubMed: 19798591]
 91. Tran CM, Shapiro IM, Risbud MV. Molecular regulation of CCN2 in the intervertebral disc: lessons learned from other connective tissues. *Matrix Biol.* 2013; 32:298–306. [PubMed: 23567513]
 92. Falke LL, Dendooven A, Leeuwis JW, Nguyen TQ, van Geest RJ, van der Giezen DM, Broekhuizen R, Lyons K, Stoop R, Kemperman H, Schlingemann R, Joles JA, Goldschmeding R. Hemizygous deletion of CTGF/CCN2 does not suffice to prevent fibrosis of the severely injured kidney. *Matrix Biol.* 2012; 31:421–431. [PubMed: 23199377]
 93. Leask A, Parapuram SK, Shi-Wen X, Abraham DJ. Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease? *J Cell Commun Signal.* 2009; 3:89–94. [PubMed: 19156539]
 94. Vial C, Gutierrez J, Santander C, Cabrera D, Brandan E. Decorin interacts with connective tissue growth factor (CTGF)/CCN2 by LRR12 inhibiting its biological activity. *J Biol Chem.* 2011; 286:24242–24252. [PubMed: 21454550]
 95. Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, Goldschmeding R. Expression of connective tissue growth factor in human renal fibrosis. *Kidney Int.* 1998; 53:853–861. [PubMed: 9551391]
 96. Schaefer L, Raslik I, Grone HJ, Schonherr E, Macakova K, Ugorcakova J, Budny S, Schaefer RM, Kresse H. Small proteoglycans in human diabetic nephropathy: discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican, and fibromodulin. *FASEB J.* 2001; 15:559–561. [PubMed: 11259366]
 97. Mozes MM, Bottinger EP, Jacot TA, Kopp JB. Renal expression of fibrotic matrix proteins and of transforming growth factor-beta (TGF-beta) isoforms in TGF-beta transgenic mice. *J Am Soc Nephrol.* 1999; 10:271–280. [PubMed: 10215326]
 98. Border WA, Okuda S, Languino LR, Ruoslahti E. Transforming growth factor-beta regulates production of proteoglycans by mesangial cells. *Kidney Int.* 1990; 37:689–695. [PubMed: 2407884]
 99. Stokes MB, Holler S, Cui Y, Hudkins KL, Eitner F, Fogo A, Alpers CE. Expression of decorin, biglycan, and collagen type I in human renal fibrosing disease. *Kidney Int.* 2000; 57:487–498. [PubMed: 10652025]
 100. Pulskens WP, Rampanelli E, Teske GJ, Butter LM, Claessen N, Luirink IK, van der Poll T, Florquin S, Leemans JC. TLR4 promotes fibrosis but attenuates tubular damage in progressive renal injury. *J Am Soc Nephrol.* 2010; 21:1299–1308. [PubMed: 20595685]
 101. Leemans JC, Butter LM, Pulskens WP, Teske GJ, Claessen N, van der Poll T, Florquin S. The role of Toll-like receptor 2 in inflammation and fibrosis during progressive renal injury. *PLoS ONE.* 2009; 4:e5704. [PubMed: 19479087]

102. Friden V, Oveland E, Tenstad O, Ebefors K, Nystrom J, Nilsson UA, Haraldsson B. The glomerular endothelial cell coat is essential for glomerular filtration. *Kidney Int.* 2011; 79:1322–1330. [PubMed: 21412215]
103. Krishnan A, Li X, Kao WY, Viker K, Butters K, Masuoka H, Knudsen B, Gores G, Charlton M. Lumican, an extracellular matrix proteoglycan, is a novel requisite for hepatic fibrosis. *Lab Invest.* 2012; 92:1712–1725. [PubMed: 23007134]
104. Mormone E, Lu Y, Ge X, Fiel MI, Nieto N. Fibromodulin, an oxidative stress-sensitive proteoglycan, regulates the fibrogenic response to liver injury in mice. *Gastroenterology.* 2012; 142:612–621. e615. [PubMed: 22138190]
105. Baghy K, Dezso K, Laszlo V, Fullar A, Peterfia B, Paku S, Nagy P, Schaff Z, Iozzo RV, Kovalszky I. Ablation of the decorin gene enhances experimental hepatic fibrosis and impairs hepatic healing in mice. *Lab Invest.* 2011; 91:439–451. [PubMed: 20956977]
106. Babelova A, Moreth K, Tsalastra-Greul W, Zeng-Brouwers J, Eickelberg O, Young MF, Bruckner P, Pfeilschifter J, Schaefer RM, Grone HJ, Schaefer L. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. *J Biol Chem.* 2009; 284:24035–24048. [PubMed: 19605353]
107. Moreth K, Brodbeck R, Babelova A, Gretz N, Spieker T, Zeng-Brouwers J, Pfeilschifter J, Young MF, Schaefer RM, Schaefer L. The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. *J Clin Invest.* 2010; 120:4251–4272. [PubMed: 21084753]
108. Popovic ZV, Wang S, Papatriantafyllou M, Kaya Z, Porubsky S, Meisner M, Bonrouhi M, Burgdorf S, Young MF, Schaefer L, Grone HJ. The proteoglycan biglycan enhances antigen-specific T cell activation potentially via MyD88 and TRIF pathways and triggers autoimmune perimyocarditis. *J Immunol.* 2011; 187:6217–6226. [PubMed: 22095710]
109. Skuginna V, Lech M, Allam R, Ryu M, Clauss S, Susanti HE, Rommele C, Garlanda C, Mantovani A, Anders HJ. Toll-like receptor signaling and SIGIRR in renal fibrosis upon unilateral ureteral obstruction. *PLoS ONE.* 2011; 6:e19204. [PubMed: 21544241]
110. Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, Alexander SI, Sharland AF, Chadban SJ. TLR4 activation mediates kidney ischemia/reperfusion injury. *J Clin Invest.* 2007; 117:2847–2859. [PubMed: 17853945]
111. Wang S, Schmauderer C, Kiss E, Schmidt C, Bonrouhi M, Porubsky S, Gretz N, Schaefer L, Kirschning CJ, Popovic ZV, Grone HJ. Recipient Toll-like receptors contribute to chronic graft dysfunction by both MyD88- and TRIF-dependent signaling. *Dis Model Mech.* 2010; 3:92–103. [PubMed: 20038715]
112. Kiss E, Popovic ZV, Bedke J, Adams J, Bonrouhi M, Babelova A, Schmidt C, Edenhofer F, Zschiedrich I, Domhan S, Abdollahi A, Schafer L, Gretz N, Porubsky S, Grone HJ. Peroxisome proliferator-activated receptor (PPAR)gamma can inhibit chronic renal allograft damage. *Am J Pathol.* 2010; 176:2150–2162. [PubMed: 20363918]
113. Zeng-Brouwers J, Beckmann J, Nastase MV, Iozzo RV, Schaefer L. De novo expression of circulating biglycan evokes an innate inflammatory tissue response via MyD88/TRIF pathways. *Matrix Biol.* 10.1016/j.matbio.2013.12.003
114. Lim AK, Tesch GH. Inflammation in diabetic nephropathy. *Mediators Inflamm.* 2012; 2012:146154. [PubMed: 22969168]
115. Thompson J, Wilson P, Brandewie K, Taneja D, Schaefer L, Mitchell B, Tannock LR. Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy. *Am J Pathol.* 2011; 179:1179–1187. [PubMed: 21723246]
116. Tannock LR. Proteoglycans can mediate renal lipoprotein retention. *Diabetologia.* 2006; 49:1115–1116. [PubMed: 16532326]
117. Zhang Y, Hu R, Wu H, Jiang W, Sun Y, Wang Y, Song Y, Jin T, Zhang H, Mao X, Zhao Z, Zhang Z. OTUB1 overexpression in mesangial cells is a novel regulator in the pathogenesis of glomerulonephritis through the decrease of DCN level. *PLoS ONE.* 2012; 7:e29654. [PubMed: 22279542]
118. Ebefors K, Granqvist A, Ingelsten M, Molne J, Haraldsson B, Nystrom J. Role of glomerular proteoglycans in IgA nephropathy. *PLoS ONE.* 2011; 6:e18575. [PubMed: 21494642]

119. Sallustio F, Costantino V, Cox SN, Loverre A, Divella C, Rizzi M, Schena FP. Human renal stem/progenitor cells repair tubular epithelial cell injury through TLR2-driven inhibin-A and microvesicle-shuttled decorin. *Kidney Int.* 2013; 83:392–403. [PubMed: 23325086]
120. Kim YM, Kim YS, Jeon SG, Kim YK. Immunopathogenesis of allergic asthma: more than the th2 hypothesis. *Allergy Asthma Immunol Res.* 2013; 5:189–196. [PubMed: 23814671]
121. Pini L, Hamid Q, Shannon J, Lemelin L, Olivenstein R, Ernst P, Lemiere C, Martin JG, Ludwig MS. Differences in proteoglycan deposition in the airways of moderate and severe asthmatics. *Eur Respir J.* 2007; 29:71–77. [PubMed: 17050562]
122. Marchica CL, Pinelli V, Borges M, Zimmer J, Narayanan V, Iozzo RV, Ludwig MS. A role for decorin in a murine model of allergen-induced asthma. *Am J Physiol Lung Cell Mol Physiol.* 2011; 300:L863–873. [PubMed: 21378022]
123. Huang J, Olivenstein R, Taha R, Hamid Q, Ludwig M. Enhanced proteoglycan deposition in the airway wall of atopic asthmatics. *Am J Respir Crit Care Med.* 1999; 160:725–729. [PubMed: 10430752]
124. de Kluijver J, Schrumph JA, Evertse CE, Sont JK, Roughley PJ, Rabe KF, Hiemstra PS, Mauad T, Sterk PJ. Bronchial matrix and inflammation respond to inhaled steroids despite ongoing allergen exposure in asthma. *Clin Exp Allergy.* 2005; 35:1361–1369. [PubMed: 16238797]
125. Roberts CR. Is asthma a fibrotic disease? *Chest.* 1995; 107:111S–117S. [PubMed: 7874987]
126. de Medeiros Matsushita M, da Silva LF, dos Santos MA, Fernezlian S, Schrumph JA, Roughley P, Hiemstra PS, Saldiva PH, Mauad T, Dolnikoff M. Airway proteoglycans are differentially altered in fatal asthma. *J Pathol.* 2005; 207:102–110. [PubMed: 16041692]
127. Westergren-Thorsson G, Chakir J, Lafreniere-Allard MJ, Boulet LP, Tremblay GM. Correlation between airway responsiveness and proteoglycan production by bronchial fibroblasts from normal and asthmatic subjects. *Int J Biochem Cell Biol.* 2002; 34:1256–1267. [PubMed: 12127576]
128. Ludwig MS, Ftouhi-Paquin N, Huang W, Page N, Chakir J, Hamid Q. Mechanical strain enhances proteoglycan message in fibroblasts from asthmatic subjects. *Clin Exp Allergy.* 2004; 34:926–930. [PubMed: 15196281]
129. Nihlberg K, Andersson-Sjoland A, Tufvesson E, Erjefalt JS, Bjermer L, Westergren-Thorsson G. Altered matrix production in the distal airways of individuals with asthma. *Thorax.* 2010; 65:670–676. [PubMed: 20685740]
130. Pini L, Torregiani C, Martin JG, Hamid Q, Ludwig MS. Airway remodeling in allergen-challenged Brown Norway rats: distribution of proteoglycans. *Am J Physiol Lung Cell Mol Physiol.* 2006; 290:L1052–1058. [PubMed: 16387756]
131. Redington AE, Roche WR, Holgate ST, Howarth PH. Co-localization of immunoreactive transforming growth factor-beta 1 and decorin in bronchial biopsies from asthmatic and normal subjects. *J Pathol.* 1998; 186:410–415. [PubMed: 10209491]
132. Redington AE, Howarth PH. Airway wall remodelling in asthma. *Thorax.* 1997; 52:310–312. [PubMed: 9196510]
133. Cho JY. Recent advances in mechanisms and treatments of airway remodeling in asthma: a message from the bench side to the clinic. *Korean J Intern Med.* 2011; 26:367–383. [PubMed: 22205837]
134. Black JL, Burgess JK, Johnson PR. Airway smooth muscle--its relationship to the extracellular matrix. *Respir Physiol Neurobiol.* 2003; 137:339–346. [PubMed: 14516736]
135. Araujo BB, Dolnikoff M, Silva LF, Elliot J, Lindeman JH, Ferreira DS, Mulder A, Gomes HA, Fernezlian SM, James A, Mauad T. Extracellular matrix components and regulators in the airway smooth muscle in asthma. *Eur Respir J.* 2008; 32:61–69. [PubMed: 18321931]
136. Yick CY, Ferreira DS, Annoni R, von der Thusen JH, Kunst PW, Bel EH, Lutter R, Mauad T, Sterk PJ. Extracellular matrix in airway smooth muscle is associated with dynamics of airway function in asthma. *Allergy.* 2012; 67:552–559. [PubMed: 22229658]
137. McParland BE, Macklem PT, Pare PD. Airway wall remodeling: friend or foe? *J Appl Physiol.* 2003; 95:426–434. [PubMed: 12794101]

138. Bottoms SE, Howell JE, Reinhardt AK, Evans IC, McAnulty RJ. Tgf-Beta isoform specific regulation of airway inflammation and remodelling in a murine model of asthma. *PLoS ONE*. 2010; 5:e9674. [PubMed: 20300191]
139. Elias JA. Airway remodeling in asthma. Unanswered questions. *Am J Respir Crit Care Med*. 2000; 161:S168–171. [PubMed: 10712368]
140. Tschumperlin DJ, Drazen JM. Mechanical stimuli to airway remodeling. *Am J Respir Crit Care Med*. 2001; 164:S90–94. [PubMed: 11734475]
141. Pasternyk SM, D'Antoni ML, Venkatesan N, Siddiqui S, Martin JG, Ludwig MS. Differential effects of extracellular matrix and mechanical strain on airway smooth muscle cells from ovalbumin- vs. saline-challenged Brown Norway rats. *Respir Physiol Neurobiol*. 2012; 181:36–43. [PubMed: 22310394]
142. Varisco BM. The pharmacology of acute lung injury in sepsis. *Adv Pharmacol Sci*. 2011; 2011:254619. [PubMed: 21738527]
143. Shao H, Lee S, Gae-Scott S, Nakata C, Chen S, Hamad AR, Chakravarti S. Extracellular matrix lumican promotes bacterial phagocytosis, and Lum^{-/-} mice show increased *Pseudomonas aeruginosa* lung infection severity. *J Biol Chem*. 2012; 287:35860–35872. [PubMed: 22865855]
144. Shao H, Scott SG, Nakata C, Hamad AR, Chakravarti S. Extracellular matrix protein lumican promotes clearance and resolution of *Pseudomonas aeruginosa* keratitis in a mouse model. *PLoS ONE*. 2013; 8:e54765. [PubMed: 23358433]
145. Wuyts WA, Agostini C, Antoniou KM, Bouros D, Chambers RC, Cottin V, Egan JJ, Lambrecht BN, Lories R, Parfrey H, Prasse A, Robalo-Cordeiro C, Verbeken E, Verschakelen JA, Wells AU, Verleden GM. The pathogenesis of pulmonary fibrosis: a moving target. *Eur Respir J*. 2013; 41:1207–1218. [PubMed: 23100500]
146. Mouratis MA, Aidinis V. Modeling pulmonary fibrosis with bleomycin. *Curr Opin Pulm Med*. 2011; 17:355–361. [PubMed: 21832918]
147. Venkatesan N, Ebihara T, Roughley PJ, Ludwig MS. Alterations in large and small proteoglycans in bleomycin-induced pulmonary fibrosis in rats. *Am J Respir Crit Care Med*. 2000; 161:2066–2073. [PubMed: 10852789]
148. Westergren-Thorsson G, Hernnas J, Sarnstrand B, Oldberg A, Heinegard D, Malmstrom A. Altered expression of small proteoglycans, collagen, and transforming growth factor-beta 1 in developing bleomycin-induced pulmonary fibrosis in rats. *J Clin Invest*. 1993; 92:632–637. [PubMed: 7688761]
149. Giri SN, Hyde DM, Braun RK, Gaarde W, Harper JR, Pierschbacher MD. Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis. *Biochem Pharmacol*. 1997; 54:1205–1216. [PubMed: 9416971]
150. Kolb M, Margetts PJ, Galt T, Sime PJ, Xing Z, Schmidt M, Gauldie J. Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. *Am J Respir Crit Care Med*. 2001; 163:770–777. [PubMed: 11254537]
151. Shimizukawa M, Ebina M, Narumi K, Kikuchi T, Munakata H, Nukiwa T. Intratracheal gene transfer of decorin reduces subpleural fibroproliferation induced by bleomycin. *Am J Physiol Lung Cell Mol Physiol*. 2003; 284:L526–532. [PubMed: 12573990]
152. Rovina N, Koutsoukou A, Koulouris NG. Inflammation and Immune Response in COPD: Where Do We Stand? *Mediators Inflamm*. 2013; 2013:413735. [PubMed: 23956502]
153. Hallgren O, Nihlberg K, Dahlback M, Bjermer L, Eriksson LT, Erjefalt JS, Lofdahl CG, Westergren-Thorsson G. Altered fibroblast proteoglycan production in COPD. *Respir Res*. 2010; 11:55. [PubMed: 20459817]
154. van Straaten JF, Coers W, Noordhoek JA, Huitema S, Flipsen JT, Kauffman HF, Timens W, Postma DS. Proteoglycan changes in the extracellular matrix of lung tissue from patients with pulmonary emphysema. *Mod Pathol*. 1999; 12:697–705. [PubMed: 10430274]
155. Noordhoek JA, Postma DS, Chong LL, Menkema L, Kauffman HF, Timens W, van Straaten JF, van der Geld YM. Different modulation of decorin production by lung fibroblasts from patients with mild and severe emphysema. *COPD*. 2005; 2:17–25. [PubMed: 17136957]

156. van Diemen CC, Postma DS, Vonk JM, Bruinenberg M, Nolte IM, Boezen HM. Decorin and TGF-beta1 polymorphisms and development of COPD in a general population. *Respir Res.* 2006; 7:89. [PubMed: 16780585]
157. Brandsma CA, Kerstjens HA, van Geffen WH, Geerlings M, Postma DS, Hylkema MN, Timens W. Differential switching to IgG and IgA in active smoking COPD patients and healthy controls. *Eur Respir J.* 2012; 40:313–321. [PubMed: 22241744]
158. Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease. *N Engl J Med.* 2004; 350:2689–2697. [PubMed: 15215485]
159. Brandsma CA, Timens W, Jonker MR, Rutgers B, Noordhoek JA, Postma DS. Differential effects of fluticasone on extracellular matrix production by airway and parenchymal fibroblasts in severe COPD. *Am J Physiol Lung Cell Mol Physiol.* 2013
160. Kunz LI, Strebus J, Budulac SE, Lapperre TS, Sterk PJ, Postma DS, Mauad T, Timens W, Hiemstra PS, Group GS. Inhaled steroids modulate extracellular matrix composition in bronchial biopsies of COPD patients: a randomized, controlled trial. *PLoS ONE.* 2013; 8:e63430. [PubMed: 23667615]
161. Larsson-Callerfelt AK, Hallgren O, Andersson-Sjoland A, Thiman L, Bjorklund J, Kron J, Nihlberg K, Bjermer L, Lofdahl CG, Westergren-Thorsson G. Defective alterations in the collagen network to prostacyclin in COPD lung fibroblasts. *Respir Res.* 2013; 14:21. [PubMed: 23406566]
162. Iozzo RV, Sanderson RD. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. *J Cell Mol Med.* 2011; 15:1013–1031. [PubMed: 21155971]
163. Goldoni S, Iozzo RV. Tumor microenvironment: Modulation by decorin and related molecules harboring leucine-rich tandem motifs. *Int J Cancer.* 2008; 123:2473–2479. [PubMed: 18798267]
164. Sofeu Feugaing DD, Gotte M, Viola M. More than matrix: the multifaceted role of decorin in cancer. *Eur J Cell Biol.* 2013; 92:1–11. [PubMed: 23058688]
165. Zhu JX, Goldoni S, Bix G, Owens RT, McQuillan DJ, Reed CC, Iozzo RV. Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis. *J Biol Chem.* 2005; 280:32468–32479. [PubMed: 15994311]
166. Csordas G, Santra M, Reed CC, Eichstetter I, McQuillan DJ, Gross D, Nugent MA, Hajnoczky G, Iozzo RV. Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. *J Biol Chem.* 2000; 275:32879–32887. [PubMed: 10913155]
167. Seidler DG, Goldoni S, Agnew C, Cardi C, Thakur ML, Owens RT, McQuillan DJ, Iozzo RV. Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. *J Biol Chem.* 2006; 281:26408–26418. [PubMed: 16835231]
168. Jung P, Menssen A, Mayr D, Hermeking H. AP4 encodes a c-MYC-inducible repressor of p21. *Proc Natl Acad Sci U S A.* 2008; 105:15046–15051. [PubMed: 18818310]
169. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. *Nat Rev Cancer.* 2012; 12:89–103. [PubMed: 22270953]
170. Schonherr E, Levkau B, Schaefer L, Kresse H, Walsh K. Decorin-mediated signal transduction in endothelial cells. Involvement of Akt/protein kinase B in up-regulation of p21(WAF1/CIP1) but not p27(KIP1). *J Biol Chem.* 2001; 276:40687–40692. [PubMed: 11546775]
171. Grant DS, Yenisey C, Rose RW, Tootell M, Santra M, Iozzo RV. Decorin suppresses tumor cell-mediated angiogenesis. *Oncogene.* 2002; 21:4765–4777. [PubMed: 12101415]
172. Neill T, Painter H, Buraschi S, Owens RT, Lisanti MP, Schaefer L, Iozzo RV. Decorin antagonizes the angiogenic network: concurrent inhibition of Met, hypoxia inducible factor 1alpha, vascular endothelial growth factor A, and induction of thrombospondin-1 and TIMP3. *J Biol Chem.* 2012; 287:5492–5506. [PubMed: 22194599]
173. Neill T, Jones HR, Crane-Smith Z, Owens RT, Schaefer L, Iozzo RV. Decorin induces rapid secretion of thrombospondin-1 in basal breast carcinoma cells via inhibition of Ras homolog gene family, member A/Rho-associated coiled-coil containing protein kinase 1. *FEBS J.* 2013; 280:2353–2368. [PubMed: 23350987]

174. Goyal A, Neill T, Owens RT, Schaefer L, Iozzo RV. Decorin activates AMPK, an energy sensor kinase, to induce autophagy in endothelial cells. *Matrix Biol.* 2013 in press.
175. Iozzo RV, Buraschi S, Genua M, Xu SQ, Solomides CC, Peiper SC, Gomella LG, Owens RC, Morrione A. Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling. *J Biol Chem.* 2011; 286:34712–34721. [PubMed: 21840990]
176. Metalli D, Lovat F, Tripodi F, Genua M, Xu SQ, Spinelli M, Alberghina L, Vanoni M, Baffa R, Gomella LG, Iozzo RV, Morrione A. The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. *Am J Pathol.* 2010; 176:2997–3006. [PubMed: 20395438]
177. Soria-Valles C, Gutierrez-Fernandez A, Guiu M, Mari B, Fueyo A, Gomis RR, Lopez-Otin C. The anti-metastatic activity of collagenase-2 in breast cancer cells is mediated by a signaling pathway involving decorin and miR-21. *Oncogene.* 2013
178. Asakura S, Kato H, Fujino S, Konishi T, Tezuka N, Mori A. Role of transforming growth factor-beta1 and decorin in development of central fibrosis in pulmonary adenocarcinoma. *Hum Pathol.* 1999; 30:195–198. [PubMed: 10029448]
179. McDoniels-Silvers AL, Nimri CF, Stoner GD, Lubet RA, You M. Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. *Clin Cancer Res.* 2002; 8:1127–1138. [PubMed: 11948124]
180. Shintani K, Matsumine A, Kusuzaki K, Morikawa J, Matsubara T, Wakabayashi T, Araki K, Satonaka H, Wakabayashi H, Iino T, Uchida A. Decorin suppresses lung metastases of murine osteosarcoma. *Oncol Rep.* 2008; 19:1533–1539. [PubMed: 18497961]
181. Liu Y, Li W, Li X, Tai Y, Lu Q, Yang N, Jiang J. Expression and significance of biglycan in endometrial cancer. *Arch Gynecol Obstet.* 2013
182. Aprile G, Avellini C, Reni M, Mazzer M, Foltran L, Rossi D, Cereda S, Iaiza E, Fasola G, Piga A. Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma. *Tumour Biol.* 2013; 34:131–137. [PubMed: 23007878]
183. Wang B, Li GX, Zhang SG, Wang Q, Wen YG, Tang HM, Zhou CZ, Xing AY, Fan JW, Yan DW, Qiu GQ, Yu ZH, Peng ZH. Biglycan expression correlates with aggressiveness and poor prognosis of gastric cancer. *Exp Biol Med.* 2011; 236:1247–1253.
184. Gu X, Ma Y, Xiao J, Zheng H, Song C, Gong Y, Xing X. Up-regulated biglycan expression correlates with the malignancy in human colorectal cancers. *Clin Exp Med.* 2012; 12:195–199. [PubMed: 21879307]
185. Modolo F, Biz MT, Martins MT, Machado de Sousa SO, de Araujo NS. Expression of extracellular matrix proteins in adenomatoid odontogenic tumor. *J Oral Pathol Med.* 2010; 39:230–235. [PubMed: 20070486]
186. Pan S, Cheng L, White JT, Lu W, Utleg AG, Yan X, Urban ND, Drescher CW, Hood L, Lin B. Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers. *OMICS.* 2009; 13:345–354. [PubMed: 19422301]
187. Weber CK, Sommer G, Michl P, Fensterer H, Weimer M, Gansauge F, Leder G, Adler G, Gress TM. Biglycan is overexpressed in pancreatic cancer and induces G1-arrest in pancreatic cancer cell lines. *Gastroenterology.* 2001; 121:657–667. [PubMed: 11522750]
188. Recktenwald CV, Leisz S, Steven A, Mimura K, Muller A, Wulfanger J, Kiessling R, Seliger B. HER-2/neu-mediated down-regulation of biglycan associated with altered growth properties. *J Biol Chem.* 2012; 287:24320–24329. [PubMed: 22582394]
189. Yamamoto K, Ohga N, Hida Y, Maishi N, Kawamoto T, Kitayama K, Akiyama K, Osawa T, Kondoh M, Matsuda K, Onodera Y, Fujie M, Kaga K, Hirano S, Shinohara N, Shindoh M, Hida K. Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells. *Br J Cancer.* 2012; 106:1214–1223. [PubMed: 22374465]
190. Li Y, Aoki T, Mori Y, Ahmad M, Miyamori H, Takino T, Sato H. Cleavage of lumican by membrane-type matrix metalloproteinase-1 abrogates this proteoglycan-mediated suppression of tumor cell colony formation in soft agar. *Cancer Res.* 2004; 64:7058–7064. [PubMed: 15466200]

191. Vij N, Roberts L, Joyce S, Chakravarti S. Lumican suppresses cell proliferation and aids Fas-Fas ligand mediated apoptosis: implications in the cornea. *Exp Eye Res.* 2004; 78:957–971. [PubMed: 15051477]
192. Sharma B, Ramus MD, Kirkwood CT, Sperry EE, Chu PH, Kao WW, Albig AR. Lumican Exhibits Anti-Angiogenic Activity in a Context Specific Manner. *Cancer Microenviron.* 2013
193. Okano T, Kondo T, Kakisaka T, Fujii K, Yamada M, Kato H, Nishimura T, Gemma A, Kudoh S, Hirohashi S. Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. *Proteomics.* 2006; 6:3938–3948. [PubMed: 16767791]
194. Matsuda Y, Yamamoto T, Kudo M, Kawahara K, Kawamoto M, Nakajima Y, Koizumi K, Nakazawa N, Ishiwata T, Naito Z. Expression and roles of lumican in lung adenocarcinoma and squamous cell carcinoma. *Int J Oncol.* 2008; 33:1177–1185. [PubMed: 19020750]
195. Brezillon S, Zeltz C, Schneider L, Terryn C, Vuillermoz B, Ramont L, Perrau C, Pluot M, Diebold MD, Radwanska A, Malicka-Blaszkiewicz M, Maquart FX, Wegrowski Y. Lumican inhibits B16F1 melanoma cell lung metastasis. *J Physiol Pharmacol.* 2009; 60(Suppl 4):15–22. [PubMed: 20083847]

HIGHLIGHTS

- Small leucine-rich proteoglycans play key signaling roles in a variety of diseases
- We critically review their roles in several renal and pulmonary diseases
- We focus primarily on the two most-studied family members, decorin and biglycan
- Biglycan is a potential target in inflammation
- Decorin may prove to be a treatment in fibrosis or cancer

Figure 1. Decorin and biglycan signaling in fibrosis and inflammation

In renal fibroblasts, through binding to IGF-IR and via the activation of the PI3K and Akt/PKB pathways and mTOR, decorin induces the translation of fibrillin-1, a regulator of TGF- β availability. In tubular epithelial cells decorin reduces apoptosis through interaction with IGF-IR and activation of downstream PI3K/Akt/PKB pathway. Additionally, decorin can bind CTGF (CCN2) and reduce the CTGF-induced levels of collagen III and fibronectin. Soluble biglycan binds to both TLR2 and 4 and via MyD88 activates the Erk, p38 and NF- κ B pathways. This leads to the synthesis of pro-IL-1 β , TNF- α , and the chemoattractants CXCL1, CXCL2, CCL3 and CCL5. The inflammasome complex NLRP3, ASC and caspase-1 can also be induced by soluble biglycan, leading to activation of caspase-1 which cleaves pro-IL-1 β to mature IL-1 β .

Abbreviations: ASC, apoptosis-associated speck-like protein containing a CARD; CCL, Chemokine (C-C motif) ligand; CTGF/CCN2, connective tissue growth factor; CXCL, Chemokine (C-X-C motif) ligand; Erk, extracellular-signal-regulated kinase; IGF-IR, insulin-like growth factor type I receptor; IL-1 β , interleukin 1 β ; mTOR, mammalian target of rapamycin; MyD88, myeloid differentiation primary response 88; NF- κ B, nuclear factor kappa-light-chain enhancer of activated B cells; NLRP3, NLR family, pyrin domain-containing 3; PI3K, phosphatidylinositol 3-kinase; TGF- β , transforming growth factor- β ; TLR, Toll-like receptor; TNF- α , tumor necrosis factor α .

Figure 2. Decorin's interference with signaling in cancer

In cancer cells, decorin binds to IGF-IR and to its ligand IGF-I at different binding sites and decreases both IGF-I-induced MAPK and Akt pathways activation leading to less level of p90RSK and p70S6K, respectively. Through binding to EGFR, decorin leads to receptor internalization and its lysosomal degradation. Following binding, EGFR gets phosphorylated and Erk1/2 are activated, leading to the transcription of the CDKN1A gene corresponding to cyclin-dependent kinase inhibitor 1, p21^{WAF1}. When the HGF receptor Met is activated following Serine62 phosphorylation, Myc is translocated to the nucleus where induces the synthesis of AP4, a repressor for the CDKN1A gene. At the same time β-catenin is also translocated to the nucleus where it is recruited to and activates TCF/LEF-related gene transcription and induces the synthesis of tumor-associated genes such as c-MYC and MYCN. When decorin binds to Met following the phosphorylation of Myc (at Threonine58) and β-catenin, both are triggered to proteasomal degradation. Through Met, decorin inhibits proangiogenic factors such as HIF-1α. Alternatively, decorin interacts with VEGFR2 thereby leading to rapid phosphorylation of AMPK and increased levels of Peg3 as well as Peg3-dependent expression of autophagy-related genes BECN1 and MAP1LC3a. This mechanism is upstream of autophagy induction under decorin stimulation. Decorin binds TLR2 and TLR4, activates MAPKs and NF-κB and induces the transcription of the TNF, IL12B, IL10 and PDCD4 genes. Decorin-induced PDCD4 leads to translational repression of IL-10. By inhibiting TGF-β signaling, decorin decreases the abundance of oncogenic microRNA-21 (miR-21) and prevents the miR-21-dependent translational repression of PDCD4 and thus reduces the levels of IL-10 protein.

Abbreviations: AMPK, 5' adenosine monophosphate-activated protein kinase; AP4, activating enhancer-binding protein; BECN1, Beclin1; CDKN1A, cyclin-dependent kinase inhibitor 1; EGFR, epidermal growth factor receptor; Erk, extracellular-signal-regulated kinase; HGF, hepatocyte growth factor; HIF-1α, hypoxia inducible factor-1α; IGF-I, insulin growth factor type I; IGF-IR, insulin-like growth factor type I receptor; IL, interleukin; MAP1LC3a, microtubule-associated protein 1 light chain 3 alpha; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; PDCD4, programmed cell death 4; Peg3, Paternally-expressed gene 3; TCF/LEF,

lymphoid enhancer-binding factor/T-cell-specific factor; TNF- α , tumor necrosis factor; TGF- β , transforming growth factor- β ; VEGFR2, vascular endothelial growth factor receptor.

Table 1
Members of the SLRP family: classification and main characteristics

The molecular weight of the unmodified protein core is given for the Homo sapiens SLRPs. GAG chains denoted are keratan sulfate (KS), chondroitin sulfate (CS) or dermatan sulfate (DS). A line denotes SLRPs with no or unknown GAG chains.

SLRP class	SLRP name	Molecular weight (kDa)	GAG chains
Class I	Asporin	43.2	-
	Biglycan	41.6	CS/DS
	Decorin	39.7	CS/DS
	ECM-2	79.8	-
	ECMX	64.2	-
Class II	Fibromodulin	43.2	KS
	Keratocan	40.5	KS
	Lumican	38.4	KS
	PRELP	43.8	KS
	Osteoadherin	49.5	KS
Class III	Epiphygan	36.6	CS/DS
	Opticin	37.3	-
	Osteoglycin	33.9	KS
Class IV	Chondroadherin	40.5	-
	Nyctalopin	52.0	-
	Tsukushi	37.8	-
Class V	Podocan	69.0	-
	Podocan-like-protein-1	56.5	-